vs
ANI PHARMACEUTICALS INC（ANIP）与Kosmos Energy Ltd.（KOS）财务数据对比。点击上方公司名可切换其他公司
Kosmos Energy Ltd.的季度营收约是ANI PHARMACEUTICALS INC的1.2倍（$294.6M vs $247.1M），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs -25.9%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -16.5%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
科斯莫斯能源是一家美国上游石油企业，总部位于得克萨斯州达拉斯。公司目前在加纳、赤道几内亚近海以及墨西哥湾开展油气生产与开发业务，在毛里塔尼亚、塞内加尔近海拥有开发项目，还在纳米比亚、圣多美和普林西比、苏里南近海持有勘探许可。
ANIP vs KOS — 直观对比
营收规模更大
KOS
是对方的1.2倍
$247.1M
营收增速更快
ANIP
高出55.5%
-25.9%
两年增速更快
ANIP
近两年复合增速
-16.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $294.6M |
| 净利润 | $27.5M | — |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | -125.7% |
| 净利率 | 11.1% | — |
| 营收同比 | 29.6% | -25.9% |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | $-0.80 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPKOS
| Q4 25 | $247.1M | $294.6M | ||
| Q3 25 | $227.8M | $311.0M | ||
| Q2 25 | $211.4M | $392.6M | ||
| Q1 25 | $197.1M | $290.1M | ||
| Q4 24 | $190.6M | $397.6M | ||
| Q3 24 | $148.3M | $407.8M | ||
| Q2 24 | $138.0M | $447.8M | ||
| Q1 24 | $137.4M | $422.3M |
净利润ANIPKOS
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-124.3M | ||
| Q2 25 | $8.5M | $-87.7M | ||
| Q1 25 | $15.7M | $-110.6M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $45.0M | ||
| Q2 24 | $-2.3M | $59.8M | ||
| Q1 24 | $18.2M | $91.7M |
营业利润率ANIPKOS
| Q4 25 | 14.1% | -125.7% | ||
| Q3 25 | 15.9% | -34.2% | ||
| Q2 25 | 6.6% | -16.2% | ||
| Q1 25 | 13.3% | -32.4% | ||
| Q4 24 | -2.3% | -8.5% | ||
| Q3 24 | -13.8% | 26.1% | ||
| Q2 24 | 3.7% | 30.2% | ||
| Q1 24 | 14.8% | 33.6% |
净利率ANIPKOS
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -40.0% | ||
| Q2 25 | 4.0% | -22.3% | ||
| Q1 25 | 8.0% | -38.1% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 11.0% | ||
| Q2 24 | -1.7% | 13.3% | ||
| Q1 24 | 13.2% | 21.7% |
每股收益（稀释后）ANIPKOS
| Q4 25 | $1.14 | $-0.80 | ||
| Q3 25 | $1.13 | $-0.26 | ||
| Q2 25 | $0.36 | $-0.18 | ||
| Q1 25 | $0.69 | $-0.23 | ||
| Q4 24 | $-0.45 | $0.00 | ||
| Q3 24 | $-1.27 | $0.09 | ||
| Q2 24 | $-0.14 | $0.12 | ||
| Q1 24 | $0.82 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $91.5M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | $540.7M | $528.6M |
| 总资产 | $1.4B | $4.7B |
| 负债/权益比越低杠杆越低 | — | 5.78× |
8季度趋势，按日历期对齐
现金及短期投资ANIPKOS
| Q4 25 | $285.6M | $91.5M | ||
| Q3 25 | $262.6M | $64.0M | ||
| Q2 25 | $217.8M | $51.7M | ||
| Q1 25 | $149.8M | $49.8M | ||
| Q4 24 | $144.9M | $85.0M | ||
| Q3 24 | $145.0M | $51.6M | ||
| Q2 24 | $240.1M | $173.8M | ||
| Q1 24 | $228.6M | $254.3M |
总债务ANIPKOS
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ANIPKOS
| Q4 25 | $540.7M | $528.6M | ||
| Q3 25 | $505.8M | $898.8M | ||
| Q2 25 | $436.8M | $1.0B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.2B | ||
| Q3 24 | $405.9M | $1.2B | ||
| Q2 24 | $455.8M | $1.1B | ||
| Q1 24 | $452.0M | $1.1B |
总资产ANIPKOS
| Q4 25 | $1.4B | $4.7B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.3B | $5.2B | ||
| Q1 25 | $1.3B | $5.3B | ||
| Q4 24 | $1.3B | $5.3B | ||
| Q3 24 | $1.3B | $5.5B | ||
| Q2 24 | $920.8M | $5.4B | ||
| Q1 24 | $914.5M | $5.4B |
负债/权益比ANIPKOS
| Q4 25 | — | 5.78× | ||
| Q3 25 | — | 3.31× | ||
| Q2 25 | — | 2.80× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $35.3M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPKOS
| Q4 25 | $30.4M | $35.3M | ||
| Q3 25 | $44.1M | $-27.6M | ||
| Q2 25 | $75.8M | $127.2M | ||
| Q1 25 | $35.0M | $-888.0K | ||
| Q4 24 | $15.9M | $175.7M | ||
| Q3 24 | $12.5M | $6.3M | ||
| Q2 24 | $17.4M | $223.7M | ||
| Q1 24 | $18.3M | $272.6M |
自由现金流ANIPKOS
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPKOS
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPKOS
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPKOS
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 3.74× | ||
| Q1 24 | 1.00× | 2.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
KOS
| Ghana Segment | $134.6M | 46% |
| Gulf Of America | $80.7M | 27% |
| Mauritania And Senegal | $54.9M | 19% |
| Equatorial Guinea Segment | $24.3M | 8% |
